Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer

Hope S Rugo; Jean-Pierre Delord; Seock-Ah Im; Patrick A Ott; Sarina A Piha-Paul; Philippe L Bedard; Jasgit Sachdev; Christophe Le Tourneau; Emilie MJ van Brummelen; Andrea Varga; Roberto Salgado; Sherene Loi; Sanatan Saraf; Dina Pietrangelo; Vassiliki Karantza; Antoinette R Tan

Journal article

Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer

Hope S Rugo, Jean-Pierre Delord, Seock-Ah Im, Patrick A Ott, Sarina A Piha-Paul, Philippe L Bedard, Jasgit Sachdev, Christophe Le Tourneau, Emilie MJ van Brummelen, Andrea Varga, Roberto Salgado, Sherene Loi, Sanatan Saraf, Dina Pietrangelo, Vassiliki Karantza, Antoinette R Tan

Clinical Cancer Research | AMER ASSOC CANCER RESEARCH | Published : 2018

DOI: 10.1158/1078-0432.CCR-17-3452

University of Melbourne Researchers

Sherene Loi Author The Sir Peter MacCallum Department of Oncology

Grants

Funding Acknowledgements

The authors thank the patients and their families, study investigators, and site personnel and Roger Dansey (Merck & Co., Inc., Kenilworth, NJ) for critical manuscript review. Medical writing and/or editorial assistance was provided by Sarita S. Shaevitz, PhD, and Amy McQuay, PhD, of the ApotheCom pembrolizumab team (Yardley, PA). This assistance was funded by Merck & Co., Inc., Kenilworth, NJ. Funding for this research was provided by Merck & Co., Inc., Kenilworth, NJ.